CPT | |
---|---|
HCPCS | |
S2120 | Low density lipoprotein (LDL) apheresis using heparin-induced extracorporeal LDL precipitation |
ICD-10 Diagnosis | |
E78.00 | Pure hypercholesterolemia, unspecified |
36516 with extracorporeal selective adsorption or filtration and plasma reinfusion (LDL apheresis) 36522 Photopheresis, extracorporeal 38205 Blood-derived hematopoietic progenitor cell harvesting for transplantation, per collection; allogeneic 38206 autologous Therapeutic Apheresis: Treatment Settings CPT Description 36511
LDL apheresis Codes: The Shorthand of Insurance Billing •CPT codes. 5-digit codes used by physicians and hospitals to bill insurers for outpatient procedures and services. •ICD-9-CM procedure codes.
For purposes of Medicare coverage, apheresis is defined as an autologous procedure, i.e., blood is taken from the patient, processed, and returned to the patient as part of a continuous procedure (as distinguished from the procedure in which a patient donates blood preoperatively and is transfused with the donated blood at a later date).
A neurologist refers a MG patient to the apheresis physician to evaluate for suitability for plasma exchange. The physician examines the patient and reviews her history and labs. The physician determines that plasma exchange is appropriate therapy.
In ICD-9-CM, the Alphabetic Index main term entry is Plasmapheresis, therapeutic which identifies code 99.71. In ICD-10-PCS, the root operation for this procedure is Pheresis with the code 6A550Z3 being assigned for this procedure.
Transplanted organ and tissue status, unspecified Z94. 9 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2022 edition of ICD-10-CM Z94. 9 became effective on October 1, 2021.
Transfusion of Nonautologous Red Blood Cells into Peripheral Vein, Percutaneous Approach. ICD-10-PCS 30233N1 is a specific/billable code that can be used to indicate a procedure.
2022 ICD-10-PCS Procedure Code 6A550Z3: Pheresis of Plasma, Single.
2022 ICD-10-CM Diagnosis Code Z94. 0: Kidney transplant status.
ICD-10 code Z94. 81 for Bone marrow transplant status is a medical classification as listed by WHO under the range - Factors influencing health status and contact with health services .
A transfusion APC will be paid to the hospital for transfusing blood once per day, regardless of the number of units transfused. Hospitals should bill for transfusion services using Revenue Code 391 “Blood Administration” and HCPCS code 36430 through 36460.
Code D64. 9 is the diagnosis code used for Anemia, Unspecified, it falls under the category of diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism. Anemia specifically, is a condition in which the number of red blood cells is below normal.
One unit of FFP has a concentration of coagulation factors similar to that of 4 to 5 units of platelet concentrates, 1 apheresis unit of platelets, and 1 unit of fresh whole blood; 1 mL/kg of FFP raises most factor levels by approximately 1%.
Billing for Pheresis and Apheresis Service Answer: If this is a reinfusion of autologous RBCs, CPT 36514 Therapeutic apheresis; for plasma pheresis includes the reinfusion.
Apheresis (say "af-uh-REE-sus") is the process of withdrawing blood, filtering something out of the blood, and then putting the filtered blood back into the body. It has different names depending on what is being filtered from the blood.
Using a type of apheresis called plasmapheresis, plasma is separated and removed from the patient's blood and replaced with a protein solution of 5 percent human albumin.
An UpToDate review on “Hypertriglyceridemia-induced acute pancreatitis” (Gelrud and Whitcomb, 2016) states that “Apheresis -- Apheresis is a term describing the general process of passing blood through a medical device to separate any components, and returning the remaining components to the body. Plasmapheresis is the removal of up to 15 % of the plasma, filtration uses a membrane to remove components by size, and therapeutic plasma exchange (TPE) is the removal of plasma and replacement with a colloid solution (e.g., albumin or plasma). TPE is the treatment modality of choice for HTGP when apheresis is needed because filters become clogged by plasma triglycerides …. We suggest treatment with apheresis, and specifically therapeutic plasma exchange (TPE) if the patient has a serum triglyceride level > 1,000 mg/dL plus lipase > 3 times the upper limit of normal and signs of hypocalcemia, lactic acidosis, or signs of worsening inflammation or organ dysfunction, and if there are no contraindications to apheresis (Grade 2C)”.
Therapeutic plasmapheresis (also known as platepheresis or plasma exchange) is performed to remove toxic elements from the bloodstream. An intravenous catheter (small tube) is placed into a vein and connected to a machine (cell separator) via plastic tubing. Blood is pumped through the tubing into the machine where it is separated into red blood cells, white blood cells and plasma. The plasma is then discarded while the other components are combined with a plasma substitute and reinfused into the individual.
In contrast, antibodies play no role in treatment with glatiramer acetate. During or after therapy with mitoxantrone, serious side effects (cardiomyopathy, acute myeloid leukemia) appeared in 0.2 to 0.4 % of cases. Plasmapheresis is limited to individual curative attempts in escalating therapy of a severe attack.
Aetna considers plasmapheresis (PP), plasma exchange (PE), or therapeutic apheresis medically necessary for any of the following indications:
This document addresses therapeutic apheresis, a procedure by which blood is removed from the body, separated into components, manipulated and returned to the individual. There are multiple pheresis procedures that are performed.
Because therapeutic apheresis does not address the underlying pathology, and due to the phenomenon of rebound antibody production, its use in most chronic diseases has been less effective than in acute, self-limiting diseases.
A single session of lipoprotein apheresis has been shown to decrease cholesterol levels by 60-70% (Padmanabhan, 2019). There are various recommendations for individual selection criteria, however, there is a lack of evidence to support the initiation of treatment at specific LDL levels.
Disorders for which apheresis is accepted as first-line therapy, either as a primary standalone treatment or in conjunction with other modes of treatment. Category II. Disorders for which apheresis is accepted as second-line therapy, either as a standalone treatment or in conjunction with other modes of treatment.
Low-density lipid apheresis or lipoprotein apheresis is considered not medically necessary when the criteria for low-density lipid apheresis or lipoprotein apheresis above are not met and for all other indications.
Multiple sclerosis (MS)-acute attack/ relapse when there has been an inadequate response to or failure of medical therapy
Thrombocytapheresis is considered not medically necessary when the criteria for thrombocytopheresis above are not met and for all other indications.
02/1986 - Provided coverage of apheresis for treatment of Guillain-Barre Syndrome and for treatment of life-threatening Systemic Lupus Erythematosus. Effective date 02/14/1986. (TN 4)
Plasmapheresis or plasma exchange as a last resort treatment of thromobotic thrombocytopenic purpura (TTP);
For purposes of Medicare coverage, apheresis is defined as an autologous procedure, i.e., blood is taken from the patient, processed, and returned to the patient as part of a continuous procedure (as distinguished from the procedure in which a patient donates blood preoperatively and is transfused with the donated blood at a later date).
The Medicare Advantage Policy Guideline documents are generally used to support UnitedHealthcare Medicare Advantage claims processing activities and facilitate providers’ submission of accurate claims for the specified services. The document can be used as a guide to help determine applicable:
For purposes of Medicare coverage, apheresis is defined as an autologous procedure, i.e., blood is taken from the patient, processed, and returned to the patient as part of a continuous procedure (as distinguished from the procedure in which a patient donates blood preoperatively and at a later date, is transfused with the donated blood).
1Procedures that use cryo-poor plasma would use HCPCS code P9044
The Coverage Appeals Process: Get What the Patient Needs; Educate the Insurer
Hospital Inpatients: Apheresis and Drug Costs Are NOT Separately Reimbursed